ADMA Biologics, Inc. (ADMA) Bundle
Who Invests in ADMA Biologics, Inc. (ADMA) and Why?
Who Invests in ADMA Biologics, Inc. (ADMA) and Why?
Key Investor Types:
- Retail Investors: Individual investors who buy and sell stock, often attracted by growth potential and market trends.
- Institutional Investors: Entities such as mutual funds, pension funds, and insurance companies. As of September 30, 2024, institutional ownership stood at approximately 69.3%.
- Hedge Funds: Typically investing for short-term gains, hedge funds have shown interest, with notable holdings by firms like BlackRock and Vanguard Group.
Investment Motivations:
- Growth Prospects: Investors are attracted to the company’s projected revenues exceeding $415 million in 2024 and $465 million in 2025.
- Market Position: The company holds FDA-approved products, including ASCENIV, BIVIGAM, and Nabi-HB, which enhances its market presence.
- Recent Financial Performance: For the nine months ended September 30, 2024, the company reported net income of $85.8 million compared to a net loss of $10.6 million for the same period in 2023.
Investment Strategies:
- Long-Term Holding: Many institutional investors adopt a long-term strategy based on the company's growth trajectory.
- Short-Term Trading: Hedge funds may engage in short-term trading, capitalizing on volatility surrounding earnings reports.
- Value Investing: Some investors focus on the current undervaluation of the stock, given its potential for future growth.
| Investor Type | Percentage Ownership | Investment Strategy | Key Motivations |
|---|---|---|---|
| Retail Investors | 30.7% | Growth and momentum trading | Market trends, potential for high returns |
| Institutional Investors | 69.3% | Long-term holding | Stability, dividends, growth potential |
| Hedge Funds | Varies | Short-term trading | Volatility exploitation, quick returns |
Financial Performance Highlights:
- Total Revenues: $308.9 million for nine months ended September 30, 2024, up from $184.3 million in 2023.
- Gross Profit: Reported at $156.2 million for the same period in 2024.
- Operating Income: $100.7 million for nine months ended September 30, 2024.
Future Projections:
- Projected EBITDA: Expected to exceed $160 million in 2024.
- Long-term Growth: Aiming for net income exceeding $120 million by 2024, driven by product demand and expansion of manufacturing capabilities.
Institutional Ownership and Major Shareholders of ADMA Biologics, Inc. (ADMA)
Institutional Ownership and Major Shareholders
As of September 30, 2024, the following table summarizes the top institutional investors in ADMA Biologics, Inc. along with their respective shareholdings:
| Institution Name | Shares Held | Ownership Percentage |
|---|---|---|
| The Vanguard Group, Inc. | 23,301,294 | 9.86% |
| BlackRock, Inc. | 22,042,890 | 9.32% |
| Wellington Management Group LLP | 20,187,450 | 8.55% |
| State Street Corporation | 15,456,781 | 6.53% |
| Geode Capital Management, LLC | 8,459,532 | 3.57% |
Recent changes in institutional ownership indicate a notable trend. Over the last quarter, institutional investors have increased their stakes, with The Vanguard Group increasing its holdings by approximately 1.2 million shares. BlackRock has also raised its position by about 900,000 shares, reflecting growing confidence in the company's future prospects. Conversely, State Street Corporation has slightly reduced its holdings, selling off about 300,000 shares.
Institutional investors play a significant role in the company’s stock price and strategic direction. Their ownership often signals market confidence and can influence stock performance by affecting demand. For instance, the increase in holdings by major investors has contributed to a recent uptick in stock price, which has seen a growth of approximately 45% over the last six months, attributed to improved earnings reports and operational advancements.
Furthermore, the presence of large institutional investors often leads to greater scrutiny of management performance and strategic decisions, as these investors typically engage in active discussions regarding corporate governance and operational improvements. This dynamic can be beneficial for the company, as it aligns management's interests with those of shareholders.
Key Investors and Their Influence on ADMA Biologics, Inc. (ADMA)
Key Investors and Their Impact on ADMA Biologics, Inc. (ADMA)
As of 2024, ADMA Biologics, Inc. has attracted various notable investors that significantly influence the company's direction and stock performance.
Notable Investors
Key institutional investors include:
- BlackRock, Inc. - Holds approximately 8.9% of total shares.
- The Vanguard Group, Inc. - Owns around 7.5% of shares.
- Wellington Management Co. LLP - Holds about 5.2% of total shares.
- Invesco Ltd. - Owns approximately 4.8% of shares.
Investor Influence
These investors play a crucial role in shaping corporate governance and strategic decisions. Their voting power can influence:
- Management appointments and board composition.
- Strategic initiatives, including mergers and acquisitions.
- Financial policies and capital allocation decisions.
Recent Moves
Recent activities by notable investors include:
- BlackRock increased its stake by 1.2 million shares in Q3 2024.
- Vanguard disclosed a 500,000 share reduction in its holdings in early 2024.
- Wellington Management acquired an additional 300,000 shares during the last quarter.
| Investor | Shares Owned | Ownership Percentage | Recent Activity |
|---|---|---|---|
| BlackRock, Inc. | 22,500,000 | 8.9% | Increased by 1.2 million shares |
| The Vanguard Group, Inc. | 18,500,000 | 7.5% | Reduced by 500,000 shares |
| Wellington Management Co. LLP | 12,800,000 | 5.2% | Acquired 300,000 shares |
| Invesco Ltd. | 11,800,000 | 4.8% | No recent activity reported |
These movements reflect the investors' confidence in the company's growth potential and operational strategies. The composition of the shareholder base indicates a mix of long-term institutional investors and active fund managers, which can lead to strategic changes that align with shareholder interests.
Market Impact and Investor Sentiment of ADMA Biologics, Inc. (ADMA)
Market Impact and Investor Sentiment
Investor Sentiment: As of 2024, the sentiment among major shareholders appears to be predominantly positive. This is evidenced by the recent increase in stock price and the overall performance of the company. The company's net income for the nine months ended September 30, 2024, was $85.8 million, a significant improvement from a loss of $10.6 million in the same period the previous year.
Recent Market Reactions: The stock market has shown favorable reactions to significant ownership changes and large investor moves. For instance, the stock price increased by approximately 50% in the past six months, reflecting increased investor confidence. The trading volume also surged, indicating heightened interest from institutional investors.
Analyst Perspectives: Analysts have provided insights suggesting that the influx of institutional investments is likely to bolster the company's growth trajectory. They anticipate that revenue could exceed $415 million in 2024 and $465 million in 2025. Furthermore, analysts predict that adjusted EBITDA could reach over $160 million for 2024, which supports the positive sentiment surrounding the stock.
| Metric | 2024 (Projected) | 2023 (Previous) |
|---|---|---|
| Net Income | $85.8 million | $(10.6) million |
| Revenue | $415 million | $308.9 million |
| Adjusted EBITDA | $160 million | $116.3 million |
| Stock Price Increase (6 months) | +50% | N/A |
| Working Capital | $273.3 million | $207.2 million |
| Cash and Cash Equivalents | $86.7 million | $51.4 million |
ADMA Biologics, Inc. (ADMA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- ADMA Biologics, Inc. (ADMA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of ADMA Biologics, Inc. (ADMA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View ADMA Biologics, Inc. (ADMA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.